Selected research
Industry Research
NSAIDs Industry Research Report 2026
Market perspective
The global NSAIDs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for NSAIDs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for NSAIDs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for NSAIDs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of NSAIDs include Cigna, Geri-Care Pharmaceuticals, GlaxoSmithKline, Kopran, Novacap, Perrigo Company, Reddy Pharmaceuticals, Sun Pharmaceutical Industries and Verywell, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global NSAIDs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
NSAIDs Market by Company
Cigna
Geri-Care Pharmaceuticals
GlaxoSmithKline
Kopran
Novacap
Perrigo Company
Reddy Pharmaceuticals
Sun Pharmaceutical Industries
Verywell
Bayer
Pfizer
Merck Sharp & Dohme
Johnson & Johnson
Abbott
NSAIDs Segment by Type
Naproxen
Nabumetone
Ibuprofen
Aspirin
Others
NSAIDs Segment by Application
Back Pain Treatment
Osteoarthritis Treatment
Other Disease Treatment
NSAIDs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NSAIDs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of NSAIDs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NSAIDs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of NSAIDs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of NSAIDs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of NSAIDs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Naproxen
- Nabumetone
- Ibuprofen
- Aspirin
- Others
Applications
- Back Pain Treatment
- Osteoarthritis Treatment
- Other Disease Treatment
Companies covered
- Cigna
- Geri-Care Pharmaceuticals
- GlaxoSmithKline
- Kopran
- Novacap
- Perrigo Company
- Reddy Pharmaceuticals
- Sun Pharmaceutical Industries
- Verywell
- Bayer
- Pfizer
- Merck Sharp & Dohme
- Johnson & Johnson
- Abbott
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global NSAIDs Market Size (2021-2032)
- 2.2.2 Global NSAIDs Sales (2021-2032)
- 2.2.3 Global NSAIDs Market Average Price (2021-2032)
- 2.3 NSAIDs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Naproxen
- 2.3.3 Nabumetone
- 2.3.4 Ibuprofen
- 2.3.5 Aspirin
- 2.3.6 Others
- 2.4 NSAIDs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Back Pain Treatment
- 2.4.3 Osteoarthritis Treatment
- 2.4.4 Other Disease Treatment
3 Market Competitive Landscape by Manufacturers
- 3.1 Global NSAIDs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global NSAIDs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global NSAIDs Revenue of Manufacturers (2021-2026)
- 3.4 Global NSAIDs Average Price by Manufacturers (2021-2026)
- 3.5 Global NSAIDs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of NSAIDs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of NSAIDs, Product Type & Application
- 3.8 Global Manufacturers of NSAIDs, Established Date
- 3.9 Global NSAIDs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Cigna
- 4.1.1 Cigna Company Information
- 4.1.2 Cigna Business Overview
- 4.1.3 Cigna NSAIDs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Cigna NSAIDs Product Portfolio
- 4.1.5 Cigna Recent Developments
- 4.2 Geri-Care Pharmaceuticals
- 4.2.1 Geri-Care Pharmaceuticals Company Information
- 4.2.2 Geri-Care Pharmaceuticals Business Overview
- 4.2.3 Geri-Care Pharmaceuticals NSAIDs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Geri-Care Pharmaceuticals NSAIDs Product Portfolio
- 4.2.5 Geri-Care Pharmaceuticals Recent Developments
- 4.3 GlaxoSmithKline
- 4.3.1 GlaxoSmithKline Company Information
- 4.3.2 GlaxoSmithKline Business Overview
- 4.3.3 GlaxoSmithKline NSAIDs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 GlaxoSmithKline NSAIDs Product Portfolio
- 4.3.5 GlaxoSmithKline Recent Developments
- 4.4 Kopran
- 4.4.1 Kopran Company Information
- 4.4.2 Kopran Business Overview
- 4.4.3 Kopran NSAIDs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Kopran NSAIDs Product Portfolio
- 4.4.5 Kopran Recent Developments
- 4.5 Novacap
- 4.5.1 Novacap Company Information
- 4.5.2 Novacap Business Overview
- 4.5.3 Novacap NSAIDs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Novacap NSAIDs Product Portfolio
- 4.5.5 Novacap Recent Developments
- 4.6 Perrigo Company
- 4.6.1 Perrigo Company Company Information
- 4.6.2 Perrigo Company Business Overview
- 4.6.3 Perrigo Company NSAIDs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Perrigo Company NSAIDs Product Portfolio
- 4.6.5 Perrigo Company Recent Developments
- 4.7 Reddy Pharmaceuticals
- 4.7.1 Reddy Pharmaceuticals Company Information
- 4.7.2 Reddy Pharmaceuticals Business Overview
- 4.7.3 Reddy Pharmaceuticals NSAIDs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Reddy Pharmaceuticals NSAIDs Product Portfolio
- 4.7.5 Reddy Pharmaceuticals Recent Developments
- 4.8 Sun Pharmaceutical Industries
- 4.8.1 Sun Pharmaceutical Industries Company Information
- 4.8.2 Sun Pharmaceutical Industries Business Overview
- 4.8.3 Sun Pharmaceutical Industries NSAIDs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Sun Pharmaceutical Industries NSAIDs Product Portfolio
- 4.8.5 Sun Pharmaceutical Industries Recent Developments
- 4.9 Verywell
- 4.9.1 Verywell Company Information
- 4.9.2 Verywell Business Overview
- 4.9.3 Verywell NSAIDs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Verywell NSAIDs Product Portfolio
- 4.9.5 Verywell Recent Developments
- 4.10 Bayer
- 4.10.1 Bayer Company Information
- 4.10.2 Bayer Business Overview
- 4.10.3 Bayer NSAIDs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Bayer NSAIDs Product Portfolio
- 4.10.5 Bayer Recent Developments
- 4.11 Pfizer
- 4.11.1 Pfizer Company Information
- 4.11.2 Pfizer Business Overview
- 4.11.3 Pfizer NSAIDs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Pfizer NSAIDs Product Portfolio
- 4.11.5 Pfizer Recent Developments
- 4.12 Merck Sharp & Dohme
- 4.12.1 Merck Sharp & Dohme Company Information
- 4.12.2 Merck Sharp & Dohme Business Overview
- 4.12.3 Merck Sharp & Dohme NSAIDs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Merck Sharp & Dohme NSAIDs Product Portfolio
- 4.12.5 Merck Sharp & Dohme Recent Developments
- 4.13 Johnson & Johnson
- 4.13.1 Johnson & Johnson Company Information
- 4.13.2 Johnson & Johnson Business Overview
- 4.13.3 Johnson & Johnson NSAIDs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Johnson & Johnson NSAIDs Product Portfolio
- 4.13.5 Johnson & Johnson Recent Developments
- 4.14 Abbott
- 4.14.1 Abbott Company Information
- 4.14.2 Abbott Business Overview
- 4.14.3 Abbott NSAIDs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Abbott NSAIDs Product Portfolio
- 4.14.5 Abbott Recent Developments
5 Global NSAIDs Market Scenario by Region
- 5.1 Global NSAIDs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global NSAIDs Sales by Region: 2021-2032
- 5.2.1 Global NSAIDs Sales by Region: 2021-2026
- 5.2.2 Global NSAIDs Sales by Region: 2027-2032
- 5.3 Global NSAIDs Revenue by Region: 2021-2032
- 5.3.1 Global NSAIDs Revenue by Region: 2021-2026
- 5.3.2 Global NSAIDs Revenue by Region: 2027-2032
- 5.4 North America NSAIDs Market Facts & Figures by Country
- 5.4.1 North America NSAIDs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America NSAIDs Sales by Country (2021-2032)
- 5.4.3 North America NSAIDs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe NSAIDs Market Facts & Figures by Country
- 5.5.1 Europe NSAIDs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe NSAIDs Sales by Country (2021-2032)
- 5.5.3 Europe NSAIDs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific NSAIDs Market Facts & Figures by Country
- 5.6.1 Asia Pacific NSAIDs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific NSAIDs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific NSAIDs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America NSAIDs Market Facts & Figures by Country
- 5.7.1 South America NSAIDs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America NSAIDs Sales by Country (2021-2032)
- 5.7.3 South America NSAIDs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa NSAIDs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa NSAIDs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa NSAIDs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa NSAIDs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global NSAIDs Sales by Type (2021-2032)
- 6.1.1 Global NSAIDs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global NSAIDs Sales Market Share by Type (2021-2032)
- 6.2 Global NSAIDs Revenue by Type (2021-2032)
- 6.2.1 Global NSAIDs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global NSAIDs Revenue Market Share by Type (2021-2032)
- 6.3 Global NSAIDs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global NSAIDs Sales by Application (2021-2032)
- 7.1.1 Global NSAIDs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global NSAIDs Sales Market Share by Application (2021-2032)
- 7.2 Global NSAIDs Revenue by Application (2021-2032)
- 7.2.1 Global NSAIDs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global NSAIDs Revenue Market Share by Application (2021-2032)
- 7.3 Global NSAIDs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 NSAIDs Value Chain Analysis
- 8.1.1 NSAIDs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 NSAIDs Production Mode & Process
- 8.2 NSAIDs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 NSAIDs Distributors
- 8.2.3 NSAIDs Customers
9 Global NSAIDs Analyzing Market Dynamics
- 9.1 NSAIDs Industry Trends
- 9.2 NSAIDs Industry Drivers
- 9.3 NSAIDs Industry Opportunities and Challenges
- 9.4 NSAIDs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst